These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24579813)

  • 21. Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia.
    van Rensburg DJ; Perng RP; Mitha IH; Bester AJ; Kasumba J; Wu RG; Ho ML; Chang LW; Chung DT; Chang YT; King CH; Hsu MC
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4098-106. PubMed ID: 20660689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
    Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS
    Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy.
    DiMondi VP; Drew RH; Chen LF
    Expert Rev Anti Infect Ther; 2011 Aug; 9(8):567-72. PubMed ID: 21819323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens.
    Hu XE; Kim NK; Gray JL; Almstead JI; Seibel WL; Ledoussal B
    J Med Chem; 2003 Aug; 46(17):3655-61. PubMed ID: 12904069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus?
    Shopsin B; Zhao X; Kreiswirth BN; Tillotson GS; Drlica K
    Int J Antimicrob Agents; 2004 Jul; 24(1):32-4. PubMed ID: 15225857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.
    Bhavnani SM; Forrest A; Hammel JP; Drusano GL; Rubino CM; Ambrose PG
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):99-101. PubMed ID: 18583085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Saravolatz LD; Stein GE; Johnson LB
    Clin Infect Dis; 2011 May; 52(9):1156-63. PubMed ID: 21467022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular characteristics and in vitro susceptibility to antimicrobial agents, including the des-fluoro(6) quinolone DX-619, of Panton-Valentine leucocidin-positive methicillin-resistant Staphylococcus aureus isolates from the community and hospitals.
    Yamamoto T; Dohmae S; Saito K; Otsuka T; Takano T; Chiba M; Fujikawa K; Tanaka M
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4077-86. PubMed ID: 17043124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis.
    Zhao M; Chi Z; Pan X; Yin Y; Tang W
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
    Critchley IA; Eckburg PB; Jandourek A; Biek D; Friedland HD; Thye DA
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii45-51. PubMed ID: 21482569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients.
    Rolston KV; Vaziri I; Frisbee-Hume S; Streeter H; LeBlanc B
    Chemotherapy; 2004 Nov; 50(5):214-20. PubMed ID: 15523180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
    Wispelwey B; Schafer KR
    Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New quinolones for the treatment of community-acquired pneumonia--contra].
    Egger M
    Dtsch Med Wochenschr; 2003 May; 128(19):1071. PubMed ID: 12736860
    [No Abstract]   [Full Text] [Related]  

  • 34. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community-acquired pneumonia.
    Bradford PA; Petersen PJ; Tuckman M; Jones CH
    Clin Microbiol Infect; 2008 Sep; 14(9):882-6. PubMed ID: 18844692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
    Casapao AM; Steed ME; Levine DP; Rybak MJ
    Expert Opin Pharmacother; 2012 Jun; 13(8):1177-86. PubMed ID: 22594846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of gemifloxacin in community-acquired pneumonia.
    Tillotson GS
    Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
    Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
    BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Barriers to the effective management of respiratory tract infections in the community.
    Saginur R
    Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.